

Freedom of Information Request	FOI 23-205	24 <sup>th</sup> April 2023
--------------------------------	------------	-----------------------------

**In line with your Freedom of Information (FOI) request procedures, please find below a list of questions to be handled in accordance with this policy.**

**Please may you tell me how many patients were initiated with each drug and indication/form below:**

The Health Board does not hold this information. Velindre University NHS Trust provide these treatments on behalf of the Health Board, therefore you will need to direct your request to [Velindre University NHS Trust](#).

<b>Title</b>	<b>NICE TA Codes</b>
<b>Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer</b>	<b>TA831</b>
<b>Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer</b>	<b>TA693</b>
<b>Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer</b>	<b>TA620</b>
<b>Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy</b>	<b>TA598</b>
<b>Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection</b>	<b>TA761</b>
<b>Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer</b>	<b>TA653</b>
<b>Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer</b>	<b>TA654</b>
<b>Acalabrutinib for treating chronic lymphocytic leukaemia</b>	<b>TA689</b>
<b>Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation</b>	<b>TA798</b>
<b>Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments</b>	<b>TA862</b>
<b>Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies</b>	<b>TA704</b>

**Level of Granularity: across all trusts combined.**

**Data periods:**

- **Monthly from January 2022 to February 2023**
- **Total yearly 2020, 2021 and 2022, for each drug and indication/form above**